Here's why the Imugene share price just got a boost

Imugene's latest announcement is rallying up investors.

| More on:
Person pointing at an increasing blue graph which represents a rising share price.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Imugene shares surge 4.24% to 17.2 cents 
  • The company has dosed its first patient in the phase 1 clinical trial of oncolytic virus, CF33-hNIS 
  • The study is aiming to recruit 100 patients across 10 trial sites in the United States and Australia 

The Imugene Limited (ASX: IMU) share price has shot up during early afternoon trade.

This comes after the company announced an update on its phase 1 clinical trial of its novel cancer-killing virus, CF33-hNIS.

Developed by City of Hope, the oncolytic virus has demonstrated in shrinking solid tumours in preclinical laboratory and animal trials. This includes colon, lung, breast, ovarian and pancreatic cancer tumours.

City of Hope is one of the largest cancer research and treatment organizations in the United States.

At the time of writing, the clinical stage immuno-oncology company's shares are 4.24% higher to 17.2 cents.

Imugene commences Vaxinia study

In its release, Imugene advised it has dosed the first patient in the phase 1 clinical trial of CF33-hNIS (Vaxinia).

This has stirred up excitement among investors, sending the Imugene share price higher.

Management noted the primary goal of the study is to evaluate the safety of CF33-hNIS when used in people with advanced solid tumours.

At first, a low dose of CF33-hNIS will be administered to cancer patients with metastatic or advanced solid tumours. This will be for those who have had at least two prior lines of standard of care treatment.

The investigational treatment will be delivered either as an injection directly into tumours or intravenously.

Once patients have been treated with CF33-hNIS and acceptable safety has been demonstrated, new study participants will progress to the next stage.

Those volunteers will receive the experimental oncolytic virus in combination with the immunotherapy pembrolizumab. The latter is an engineered antibody that improves the immune system's ability to fight cancer-causing cells.

The study aims to recruit 100 patients across approximately 10 sites in the United States and Australia.

The trial is anticipated to run for approximately 24 months and will be funded from Imugene's existing cash reserves.

Imugene managing director and CEO Leslie Chong commented:

The dosing of the first patient in our Vaxinia study is a significant milestone for Imugene and clinicians faced with the challenge of treatment for metastatic advanced solid tumours.

Professor Yuman Fong and the City of Hope team have provided outstanding research. In addition to the positive preclinical results, we're incredibly eager to unlock the potential of Vaxinia and the oncolytic virotherapy platform.

Imugene share price snapshot

Despite today's gains, the Imugene share price has been on a trending decline over the past 12 months. Its shares are down almost 50%, with year to date losses of around 57%.

The company's shares hit a 52-week low of 15 cents last week, before moving in circles.

Based on the current price, Imugene has a market capitalisation of roughly $965.05 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »

A man looking at his laptop and thinking.
Healthcare Shares

Should you buy the dip in the ResMed share price?

Let's see what one leading broker is saying following yesterday's pullback.

Read more »

A woman puts up her hands and looks confused while sitting at her computer.
Healthcare Shares

Down 5%: What's going on with the ResMed share price?

Let's see what has spooked investors today and caused them to push the sell button.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Guess which ASX 300 stock is jumping 11% on big news

This stock is having a day to remember on Thursday. But why?

Read more »

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Trump executive order to hit these 3 ASX pharmaceutical stocks

Donald Trump’s new executive order caused these 3 ASX pharmaceutical stocks to crash on Monday.

Read more »